JP2012526544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526544A5 JP2012526544A5 JP2012510423A JP2012510423A JP2012526544A5 JP 2012526544 A5 JP2012526544 A5 JP 2012526544A5 JP 2012510423 A JP2012510423 A JP 2012510423A JP 2012510423 A JP2012510423 A JP 2012510423A JP 2012526544 A5 JP2012526544 A5 JP 2012526544A5
- Authority
- JP
- Japan
- Prior art keywords
- pde4d7
- expression
- prostate cancer
- sample
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010060862 Prostate cancer Diseases 0.000 claims 31
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 31
- 239000005556 hormone Substances 0.000 claims 30
- 229940088597 hormone Drugs 0.000 claims 30
- 230000003211 malignant effect Effects 0.000 claims 26
- 108090000623 proteins and genes Proteins 0.000 claims 26
- 239000000523 sample Substances 0.000 claims 23
- 102000004169 proteins and genes Human genes 0.000 claims 19
- 238000000034 method Methods 0.000 claims 14
- 238000012544 monitoring process Methods 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 238000003018 immunoassay Methods 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 206010004385 Benign neoplasm of prostate Diseases 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 4
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 238000010324 immunological assay Methods 0.000 claims 4
- 108091070501 miRNA Proteins 0.000 claims 4
- 239000002679 microRNA Substances 0.000 claims 4
- 230000004936 stimulating effect Effects 0.000 claims 4
- 108091023037 Aptamer Proteins 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 3
- 239000013068 control sample Substances 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 108091005461 Nucleic proteins Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 239000000816 peptidomimetic Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 238000012360 testing method Methods 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
- 108700039887 Essential Genes Proteins 0.000 claims 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims 1
- 101001067140 Homo sapiens Porphobilinogen deaminase Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 102100034391 Porphobilinogen deaminase Human genes 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000003281 allosteric effect Effects 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 238000013480 data collection Methods 0.000 claims 1
- 239000012649 demethylating agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000001808 exosome Anatomy 0.000 claims 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 239000013049 sediment Substances 0.000 claims 1
- 210000000582 semen Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09159960 | 2009-05-12 | ||
| EP09159960.5 | 2009-05-12 | ||
| EP09169739 | 2009-09-08 | ||
| EP09169739.1 | 2009-09-08 | ||
| PCT/IB2010/052072 WO2010131194A1 (en) | 2009-05-12 | 2010-05-11 | Phosphodiesterase 4d7 as marker for malignant, hormone-sensitive prostate cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015178795A Division JP6246167B2 (ja) | 2009-05-12 | 2015-09-10 | 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012526544A JP2012526544A (ja) | 2012-11-01 |
| JP2012526544A5 true JP2012526544A5 (https=) | 2013-06-27 |
Family
ID=42352017
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510423A Pending JP2012526544A (ja) | 2009-05-12 | 2010-05-11 | 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７ |
| JP2015178795A Active JP6246167B2 (ja) | 2009-05-12 | 2015-09-10 | 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７ |
| JP2017092325A Active JP6588496B2 (ja) | 2009-05-12 | 2017-05-08 | 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７ |
| JP2019104594A Pending JP2019205431A (ja) | 2009-05-12 | 2019-06-04 | 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015178795A Active JP6246167B2 (ja) | 2009-05-12 | 2015-09-10 | 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７ |
| JP2017092325A Active JP6588496B2 (ja) | 2009-05-12 | 2017-05-08 | 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７ |
| JP2019104594A Pending JP2019205431A (ja) | 2009-05-12 | 2019-06-04 | 悪性のホルモン感受性前立腺がんのマーカーとしてのホスホジエステラーゼ４ｄ７ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8778621B2 (https=) |
| EP (1) | EP2430190B1 (https=) |
| JP (4) | JP2012526544A (https=) |
| KR (2) | KR102110469B1 (https=) |
| CN (1) | CN102439176B (https=) |
| BR (1) | BRPI1007704A2 (https=) |
| DK (1) | DK2430190T3 (https=) |
| ES (1) | ES2707598T3 (https=) |
| WO (1) | WO2010131194A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2700877T3 (es) * | 2009-05-12 | 2019-02-19 | Koninklijke Philips Nv | Fosfodiesterasa 4D7 como marcador de cáncer de próstata |
| KR102110469B1 (ko) * | 2009-05-12 | 2020-05-14 | 코닌클리케 필립스 엔.브이. | 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7 |
| GB201322034D0 (en) | 2013-12-12 | 2014-01-29 | Almac Diagnostics Ltd | Prostate cancer classification |
| GB201504763D0 (en) | 2015-03-20 | 2015-05-06 | Mironid Ltd | Compounds and uses |
| JP6745820B2 (ja) * | 2015-05-29 | 2020-08-26 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 前立腺がん予後判定の方法 |
| JP6743056B2 (ja) * | 2015-05-29 | 2020-08-19 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 前立腺がん予後判定の方法 |
| KR101663675B1 (ko) | 2016-07-27 | 2016-10-07 | 강성훈 | 유체 흐름 유도장치 |
| GB201616439D0 (en) | 2016-09-28 | 2016-11-09 | Mironid Limited | Compounds and uses |
| KR102546357B1 (ko) * | 2016-12-01 | 2023-06-22 | 코닌클리케 필립스 엔.브이. | 인간 포스포다이에스테라제 4d 변이체 7 발현에 기초한 위험 점수 |
| EP3502280A1 (en) * | 2017-12-21 | 2019-06-26 | Koninklijke Philips N.V. | Pre-surgical risk stratification based on pde4d7 expression and pre-surgical clinical variables |
| EP3546598A1 (en) * | 2018-03-29 | 2019-10-02 | Koninklijke Philips N.V. | Post-surgical risk stratification based on pde4d variant expression, selected according to tmprss2-erg fusion status, and post-surgical clinical variables |
| GB201805527D0 (en) | 2018-04-04 | 2018-05-16 | Mironid Ltd | Compounds and their use as pde4 activators |
| US20210318324A1 (en) | 2018-07-05 | 2021-10-14 | The Board Of Regents Of The University Of Oklahoma | Gene signatures for cancer characterization and methods of use |
| EP3636779A1 (en) * | 2018-10-11 | 2020-04-15 | Koninklijke Philips N.V. | Pre-surgical risk stratification based on pde4d7 and dhx9 expression |
| CN111198270B (zh) * | 2018-11-16 | 2023-04-07 | 山东泽济生物科技有限公司 | 一种用于甘油醛-3-磷酸脱氢酶磁微粒化学发光检测试剂盒及其制备方法 |
| EP4608430A1 (en) | 2022-10-27 | 2025-09-03 | Koninklijke Philips N.V. | Treatment of prostate cancer by promoting pde4d7 |
| EP4360711A1 (en) * | 2022-10-27 | 2024-05-01 | Koninklijke Philips N.V. | Treatment of prostate cancer by promoting pde4d7 |
| EP4600377A1 (en) | 2024-02-12 | 2025-08-13 | Koninklijke Philips N.V. | Prediction of an outcome of a subject suffering from a glioma |
| CN121548649A (zh) | 2023-07-18 | 2026-02-17 | 皇家飞利浦有限公司 | 预测患有神经胶质瘤的受试者的结果 |
| EP4603836A1 (en) | 2024-02-13 | 2025-08-20 | Koninklijke Philips N.V. | Prediction of an outcome of a prostate cancer subject |
| EP4620461A1 (en) | 2024-03-22 | 2025-09-24 | Koninklijke Philips N.V. | Treatment of prostate cancer by inhibiting short pde4d isoforms |
| CN118726352B (zh) * | 2024-06-28 | 2025-11-07 | 山东大学 | 启动子元件及其在3-羟基丙酸生物合成中的应用 |
| EP4722388A1 (en) | 2024-10-03 | 2026-04-08 | Koninklijke Philips N.V. | Prediction of an outcome of a subject suffering from acute myoloid leukemia |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6261562B1 (en) * | 1997-02-25 | 2001-07-17 | Corixa Corporation | Compounds for immunotherapy of prostate cancer and methods for their use |
| HUP0203035A3 (en) * | 1998-07-14 | 2007-12-28 | Corixa Corp | Compositions and methods for therapy and diagnosis of prostate cancer |
| EE200300360A (et) | 2001-01-31 | 2003-12-15 | Pfizer Products Inc. | PDE4 isosüümide inhibiitoritena kasutatavad nikotiinamiidi biarüülderivaadid |
| IS7221A (is) * | 2001-11-15 | 2004-04-15 | Memory Pharmaceuticals Corporation | Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra |
| US20030220273A1 (en) * | 2002-05-15 | 2003-11-27 | Isis Pharmaceuticals Inc. | Antisense modulation of phosphodiesterase 4D expression |
| WO2004042389A2 (en) | 2002-11-08 | 2004-05-21 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d) |
| CA2542656A1 (en) * | 2003-10-16 | 2005-05-06 | Genomic Health, Inc. | Qrt-pcr assay system for gene expression profiling |
| CN101018874A (zh) * | 2004-08-13 | 2007-08-15 | 千年药品公司 | 用于鉴定、评估、预防和治疗前列腺癌的基因、组合物、试剂盒和方法 |
| US7250416B2 (en) | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
| NZ564223A (en) * | 2005-05-13 | 2011-03-31 | Univ California | Diarylhydantoin compounds for treating hormone refractory prostate cancer |
| AU2007252192B2 (en) * | 2006-05-19 | 2013-10-17 | Topigen Pharmaceuticals Inc. | Oligonucleotides affecting expression of phosphodiesterases |
| AU2007271232A1 (en) * | 2006-07-03 | 2008-01-10 | Exonhit Therapeutics Sa | Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics |
| US9939441B2 (en) * | 2006-07-21 | 2018-04-10 | Epigenomics Ag | Methods and nucleic acids for analyses for cellular proliferative disorders |
| ES2565053T3 (es) * | 2007-11-23 | 2016-03-31 | Epigenomics Ag | Métodos y ácidos nucleicos para el análisis de metilación de CpG asociada con el desarrollo de trastornos proliferativos de células de próstata |
| ES2700877T3 (es) * | 2009-05-12 | 2019-02-19 | Koninklijke Philips Nv | Fosfodiesterasa 4D7 como marcador de cáncer de próstata |
| KR102110469B1 (ko) * | 2009-05-12 | 2020-05-14 | 코닌클리케 필립스 엔.브이. | 악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7 |
-
2010
- 2010-05-11 KR KR1020177037100A patent/KR102110469B1/ko active Active
- 2010-05-11 DK DK10726250.3T patent/DK2430190T3/en active
- 2010-05-11 US US13/320,050 patent/US8778621B2/en active Active
- 2010-05-11 ES ES10726250T patent/ES2707598T3/es active Active
- 2010-05-11 EP EP10726250.3A patent/EP2430190B1/en active Active
- 2010-05-11 WO PCT/IB2010/052072 patent/WO2010131194A1/en not_active Ceased
- 2010-05-11 JP JP2012510423A patent/JP2012526544A/ja active Pending
- 2010-05-11 BR BRPI1007704-9A patent/BRPI1007704A2/pt not_active Application Discontinuation
- 2010-05-11 KR KR1020117029706A patent/KR20120036842A/ko not_active Ceased
- 2010-05-11 CN CN201080020794.8A patent/CN102439176B/zh active Active
-
2015
- 2015-09-10 JP JP2015178795A patent/JP6246167B2/ja active Active
-
2017
- 2017-05-08 JP JP2017092325A patent/JP6588496B2/ja active Active
-
2019
- 2019-06-04 JP JP2019104594A patent/JP2019205431A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526544A5 (https=) | ||
| JP2017184729A5 (https=) | ||
| CN106796239B (zh) | 用于诊断胰腺癌的组合物以及使用其诊断胰腺癌的方法 | |
| JP6774925B2 (ja) | 性別に基づく疾病の識別・評価・予防及び治療を含む、肺病の識別・評価・予防及び治療のための方法並びにそのキット | |
| RU2011150279A (ru) | Фосфодиэстераза 4d7 как маркер рака предстательной железы | |
| JP5224309B2 (ja) | 卵巣明細胞腺癌に特異的に発現しているタンパク質とその応用 | |
| WO2012129325A1 (en) | Molecular analysis of tumor samples | |
| KR20170130441A (ko) | 암 진단용 바이오마커 패널 | |
| JP6983221B2 (ja) | 大腸癌の併用検査 | |
| EP2933639A1 (en) | S100p and Hyaluronic acid as biomarkers for metastatic breast cancer | |
| Xu et al. | Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma | |
| US20130210667A1 (en) | Biomarkers for Predicting Kidney and Glomerular Pathologies | |
| US20170322216A1 (en) | Pancreatic cancer diagnostic | |
| JP2012526543A5 (https=) | ||
| WO2014198995A1 (es) | Biomarcadores para el diagnóstico y respuesta al tratamiento en cáncer de páncreas | |
| RU2011150291A (ru) | Фосфодиэстераза-9а в качестве маркера злокачественной опухоли предстательной железы | |
| US20240077487A1 (en) | Method for the detection of lung cancer | |
| JP7558391B2 (ja) | バフィーコート試料に使用するための膵臓癌診断用組成物 | |
| JP2013213774A (ja) | 結核検査用バイオマーカー | |
| TW201930881A (zh) | 大腸直腸腺瘤之檢測及治療方法 | |
| JP7614477B2 (ja) | 間質性肺炎のタンパク質診断バイオマーカー | |
| JP6691337B2 (ja) | 膀胱癌患者の予後を予測するための方法 | |
| Kim et al. | Combined Application of CEA, CA 15-3, and CA 27-29 for the Evaluation of Diagnostic Performance in Canine Mammary Gland Tumors | |
| US20240241130A1 (en) | Biomarker for predicting response to immune checkpoint inhibitor | |
| EP2876442A1 (en) | Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer |